INTRODUCTION
============

New psychoactive substances (NPS) have completely modified the drug scene and the current landscape of addiction \[[@R1]\]. Synthetic substances, such as substituted or synthetic cathinones, also known as « legal highs », are a group of β-ketone amphetamine compounds derived from cathinone, the active stimulant in the khat plant. These drugs, still not controlled by international laws, are often produced and used to mimic the effects of controlled drugs such as cocaine, methylenedioxymethamphetamine (MDMA, ecstasy), and methamphetamine. NPS can appear on the market either under the guise of a controlled drug or as an alternative to a controlled drug \[[@R2]\]. In this way, 4-methylamphetamine was sold directly on the illicit drug market as amphetamine.

Synthetic cathinones and synthetic cannabinoids represent more than two thirds of the NPS available in this new drug market. The overwhelming majority of synthetic cathinones is produced in China and South East Asian countries (3). Mephedrone (4-methylmethcathinone), methylone (3,4-methylenedioxymethcathinone), 3,4- methylenedioxypyrovalerone (MDPV), methylethcathinone (4-MEC), 3-fluoromethcathinone (3-FMC), 4-fluoromethcathinone (4-FMC), buphedrone (alpha-methylamino-butyrophenone), butylone (beta-keto-N-methyl-3,4-benzodioxyolybutanamine), methedrone (4-methoxymethcathinone), pentedrone (α-methylaminovalerophenone) and naphyrone (naphthylpyrovalerone) are some of the most well-known synthetic cathinones (Table **[1](#T1){ref-type="table"}**) \[[@R4]\].

The Drug Enforcement Administration (DEA) has noted that the terminology of synthetic cathinones tends to have a glamorous aura including « Meow Meow », « Bliss », « Energy-1 », « Hurricane Charlie », « White rush », « Bloom », « Blue magic », « Blue silk », « Cloud 9 », « Cloud 10 », « Mind Candy », « Rocket Fuel », « Sextasy », and « Torpedo ». All these compounds are intentionally mislabeled and sold on-line under slang terms such as bath salts, plant food, plant feeders and research chemicals. They are sometimes labeled « not for human use » or « not tested for hazards or toxicity » \[[@R3]\]. Their street price in the US is approximately \$25--35 per half gram package, while in Europe prices range between 18 and 25 € per gram \[[@R1]\].

Constant modification of the chemical structure by covert laboratories allows manufacturers to stay one step ahead of the legal process. The *Internet* has emerged as the new marketplace for NPS, playing a major role in providing information on acquisition, synthesis, extraction, identification, and substance use. Manufacturers, suppliers, retailers, website-hosting and payment processing services may all be based on internet in different countries \[[@R5]\], making this new drug business particularly difficult to be controlled. Furthermore, the growing use of anonymised illegal networks (« Darknet ») for the sale of drugs to dealers and users adds to these challenges. In 2013, 651 websites selling « legal highs » to Europeans were identified \[[@R1]\].

The main sources providing information for the study of NPS are the European Monitoring Center for Drugs and Drug Abuse (EMCDDA) (reporting form, risk assessment report, drug profile), the European Union Early Warning System (EU-EWS) reports, the ESPAD School Survey Project, and the National Reitox reports as well as official governmental and international organizations documents, the *Internet* underground and governmental websites and the discussion groups \[[@R1]\]. The Psychonaut Web Mapping Project is a 2-year European Union-funded project aiming at developing a web scanning system to identify and categorize novel recreational drugs/psychoactive compounds and new trends in drug use based on information available on the *Internet* \[[@R6]\]. The draft European Drug Emergencies Network (EuroDEN) is also funded by Europe to identify the consumption of NPS among patients visiting emergency departments and analyze any differences between countries \[[@R7]\].

The rapid spread of NPS forces member countries of the European Union to adapt their response to the potential new dangers that may cause. In October 2011, mephedrone, MDPV and methylone were temporarily classified in the US as Schedule I controlled substances \[[@R8]\]. Additionally, a permanent Schedule I distinction was attributed in July 2012 to mephedrone and MDPV and further in 2013 to methylone \[[@R9],[@R10]\]. Similarly, in July 2012, synthetic cathinones and derivatives were classified as illicit substances by the *Agence Nationale de Sécurité du Médicament*(ANSM) in France \[[@R11]\].

To date, not only health actors but also the general public need to be clearly informed and aware of dangers resulting from NPS spread and use \[[@R12]\]. Here, we review the major clinical effects of synthetic cathinones to highlight their impact on public health. A literature search was conducted from 2009 to 2014 based on PubMed, Google Scholar, Erowid, and governmental websites, using the following keywords alone or in combination: "new psychoactive substances", "synthetic cathinones", "substituted cathinones", "mephedrone", "methylone", "MDPV", "4-MEC", "addiction", and "substance use disorder".

HISTORY OF SYNTHETIC CATHINONES
===============================

*Catha edulis* was discovered in Yemen by an eighteenth century botanist called Peter Forskal \[[@R13]\]. The fresh leaves of the shrub *Catha edulis* are chewed and occasionally brewed as tea in the Arabian Peninsula and in certain regions of Eastern Africa due to their stimulant effects \[[@R14]\]. Cathinone is the stimulant alkaloid found in the leaves of the khat bush. Cathinone was found to be chemically similar to ephedrine, cathine and other amphetamines. It produces amphetamine-like psychostimulatory effects, including euphoria, alertness and psychomotor hyperactivity, but its potency appears to be lower than that of amphetamine \[[@R15]\]. Many designer drugs were first synthesized by chemists in the pharmaceutical industry or in academia who were investigating potential new pharmaceuticals \[[@R16]\]. Methcathinone, synthesized in the first half of the 20^th^ century \[[@R17]\], was the first synthetic cathinone with reports of abuse beginning in the early nineties \[[@R18]\]. Mephedrone and MDPV were first described in 1929 in the *Bulletin de la Société Chimique de France* \[[@R17]\] and in 1967 \[[@R19]\], respectively. Their abuse was not reported until the early 21^st^ century, when they were claimed to be legal alternatives to MDMA on *Internet* drug websites \[[@R20]\]. Mephedrone had been the first synthetic cathinone detected by European authorities in November 2007 and notified *via*the EU-EWS in March 2008 \[[@R21]\]. By 2010, mephedrone was detected and seized in 28 European countries \[[@R22]\]. According to the 2010 Europol--EMCDDA Joint Report, mephedrone was usually found in combination with other synthetic cathinones including methylone, butylone, ethylcathinone, methoxymethcathinone, and fluoromethcathinone \[[@R22]\]. In addition, other associated substances were found including MDMA, mCPP, lactose, and caffeine \[[@R21]\]. Methylone was first reported in 2004 as a liquid solution sold as vanilla-scented room odoriser \[[@R23]\]. Furthermore, methylone was sold *via*the *Internet* and in headshops using plastic tubes containing 5 ml liquid called "Explosion" \[[@R24]\]. MDPV was first detected in Japan in 2006, in Germany in 2007, in Finland in 2008 and in the UK and Poland after the ban on mephedrone in 2010. Butylone, also known as bk-MBDB, was first synthesized by Koeppe and collaborators in 1967. It has been available at least since 1994 but its popularity on the synthetic drug market remains marginal \[[@R24]\].

EPIDEMIOLOGICAL DATA
====================

Data on synthetic cathinones use are still limited. Available evidence suggests that in most countries, use of NPS including cathinones use remains low in the general population. The limited number of countries that have included synthetic cathinones in recent general population surveys indicated prevalence rates of 1 % or less among adults. Repeated surveys about NPS are only available in England and Wales \[[@R1]\]. By 2010, mephedrone was the third most commonly abused drug in the UK. During 2013, eighty-one NPS including seven synthetic cathinones were notified for the first time to the EU-EWS by one state member \[[@R1]\]. In France, MDPV and 4-MEC were among the 10 most popular NPS sold online during 2010-2011, \[[@R25]\]. According to the UK National Poisons Information Service, reported cases of cathinone-related toxicity increase from none in 2009 to over 600 cases in 2010 \[[@R26]\]. The Drug Abuse Warning Network (DAWN) reported that 22904 emergency department visits were due to bath salt exposures in 2011 \[[@R27]\]. Five per cent of the young Europeans declared that they have used NPS at least once, with higher prevalence observed in the UK, Ireland, Latvia, and Poland \[[@R22]\]. In a 2010 national survey, 0.7% of the Spanish students declared the use of "legal highs" during their lifetime and 0.4% mephedrone. In the same year, about 20% of 14-20 year-old UK individuals reported mephedrone use \[[@R28]\].

Based on different surveys, the use of mephedrone rapidly increased to reach the level of ecstasy use (1.4%) and even the level of cocaine use (4.4%) among the participants to the festive scene \[[@R1]\]. For both mephedrone and "legal highs", prevalence of use in Northern Ireland was estimated at 2 % during lifetime and at 1 % during the previous year. Lifetime prevalence levels were higher among the 15 to 24-year aged group (6 %). NPS (previous year use, 4%) were the second most frequently reported illicit drugs after cannabis (previous year use, 6 %). In 2012-2013, last year use of mephedrone among adults (16--59 years old) was estimated at 0.5 %. A survey of individuals attending "gay friendly" nightclubs in South-East London in 2011 found that, among the 313 participants, lifetime use of a "legal high" and mephedrone was 65.8 % and 63.8 %, respectively \[[@R29]\]. A survey of UK regular clubbers showed a decrease in the use of mephedrone in the previous year (from 19.5 % in 2011 to 13.8 % in 2012). By 2012, 128 mephedrone-associated fatalities had been reported \[[@R30]\].

The injection of synthetic cathinones is reported rarely and is restricted to specific groups of high-risk drug users (Austria, Belgium, the Czech Republic, France, Germany, Ireland, Poland, Spain and the UK). However, in Hungary and Romania, a more significant prevalence of synthetic cathinones injection was identified among large cohorts of drug users \[[@R31]\].

PATTERNS OF USE
===============

Populations of Users
--------------------

Various populations of psychoactive drug users use NPS \[[@R1]\]. Profiles of synthetic cathinone addicts and abusers are limited to surveys of UK mephedrone users and individual case reports of toxicity \[[@R15]\]. There are increasing concern about some sub-groups of gay men involved in « Chem Sex Parties » \[[@R32]\]. Synthetic cathinones are typically used in parallel or in combination with other drugs such as methamphetamine (UK), GBL/GHB, cocaine (France) and sildenafil to enhance sexual experiences. Parties can last from few hours up to many days with the subjects frequently engaging in risky sexual practices (i.e. not using condoms, sharing multiple partners) \[[@R31]\]. There is an increased risk of transmission of hepatitis C, human immunodeficiency virus (HIV) and other sexually transmitted diseases.

Analysis of the current data also indicates the emergence of a population of young adults attending techno-alternative parties. Occasional drug users may use the *Internet* to acquire some NPS. Opioid and cocaine users may switch their drug consumption to cathinones or include them in their drug-using repertoire. E-trip reports should be considered by clinicians because of the shared experiences, mostly on private places between users or *via*dedicated *Internet* forums. These provide valuable information on consumption patterns.

### Routes of Administration

Synthetic cathinones are not only frequently used as white powder or crystalline mixtures (bath salts) but are also taken orally as tablets \[[@R33]\]. Users frequently practice « keying » (snorting powder *via*a key) and « bombing » (ingesting powder rolled up in cigarette paper) \[[@R15]\]. The rapid onset of action from insufflation combined with the prolonged effects of ingestion results in immediate and sustained intoxication \[[@R15]\]. Rectal administration, gingival delivery, inhalation, intramuscular injection are less common routes \[[@R34]\]. There have been occasional reports of synthetic cathinones inserted into the eye (« eyeballing ») \[[@R35]\].

The intravenous route for cathinones or « slamming », (including mephedrone, MDPV, 4-MEC, and pentedrone) represents a major health concern \[[@R36]\]. Mixing mephedrone with heroin in a « speedball » type of use was also documented. Young drug users have been reported to start their injecting career with cathinones in some recreational settings. Similarly, long-term abstinent ex-opiate and ex-cocaine users, drug treatment clients, prisoners and men who have sex with men seem to be keen to inject cathinones \[[@R31]\].

EXPERIMENTAL DATA ON THE PHARMACOLOGY OF SYNTHETIC CATHINONES
=============================================================

Studies investigating mechanisms of action and toxicity of cathinones are sparse. Case reports or small case series describe features of toxicity, but confounding factors limit any definitive conclusions. Patients have usually consumed several drugs simultaneously. Features attributed to cathinones could be influenced and even mimicked by their underlying psychiatric and medical diseases. None of these reports have investigated the dose-effect relationships in the absence of human volunteer studies. To fill this gap, experimental studies, even though still rare, are helpful.

Synthetic cathinones-related effects rely on two major mechanisms, i.e. monoamine uptake blockade resulting from transporter inhibition and increased monoamine release as well as the combination of these two mechanisms (Table **[2](#T2){ref-type="table"}**) \[[@R40]\]. Cathinones are all potent inhibitors of norepinephrine reuptake transporter, but marked differences exist in their inhibition profiles regarding dopamine and serotonin reuptake transporters as well as their ability to release monoamines, possibly explaining clinical differences reported in their effects and toxicities. MDPV acts as a potent and selective monoamine uptake blockers but has less impact on monoamine release than cocaine. Mephedrone and methylone act not only as nonselective monoamine uptake inhibitors like cocaine but also increase serotonin release similarly to MDMA. Cathinone highly inhibits dopamine but is a less potent serotonine reuptake transporter.

Synthetic cathinones constantly increased locomotor activity. MDPV is at least 10 times more potent than cocaine at producing locomotor activation and stereotypies \[[@R41]\], while mephedrone-induced effects on locomotor activity are similar to MDMA but lower than amphetamine \[[@R42]\]. Interestingly, response to MDPV is biphasic with increased activity at lower doses and suppression of activity at higher doses. Stereotypes, observed at elevated doses, are present with MDPV and mephedrone but not methylone. Effects on memory and learning behavior in rodents are imperfectly studied, with demonstrated long-term reduction in working memory by mephedrone but no significant effects assessed with methylone \[[@R43]\]. Mephedrone is an entactogenic drug with similar effects to MDMA, able to increase social interaction among rats \[[@R44]\].

Drug discriminative studies represent an effective model to investigate subjective drug effects in humans. Mice reliably discriminate MDPV from saline and cumulative doses of MDPV, MDMA and methamphetamine fully substituted for MDPV training stimulus \[[@R45]\]. In rats, MDPV, methylone, mephedrone, naphyrone, and butylone can fully substitute for the discriminative stimulus effects of cocaine and methamphetamine. Mephedrone effects are comparable to those of MDMA, cocaine and methamphetamine.

Acquisition of self-administration with MDPV is obtained with a greater potency and efficacy than with methamphetamine \[[@R46]\]. Escalation of intake is also observed at higher rather than lower MDPV doses \[[@R47]\]. These data highly suggest that MDPV may possess a unique reinforcing profile among psychostimulants.

CLINICAL TOXICOLOGY
===================

General Data on Toxicity
------------------------

Synthetic cathinone causes amphetamine-like psychoactive and sympathomimetic effects. They are mainly used for social and economic reasons in addition to their stimulant properties, often serving as replacement for others illicit stimulant drugs \[[@R37]\]. Psychotropic effects of substituted cathinones are individual-, dose- and route of administration-dependent \[[@R34]\]. The primary effects sought by users include increased alertness, empathy, euphoria, openness in communication, talkativeness, intensification of sensory experiences, music sensitivity, reduced appetite, insomnia, sexual performance, increased sociability and capacity to work \[[@R38]\].

Users report a number of negative physical and psychiatric effects associated with synthetic cathinones \[[@R3]\]. The main NPS adverse effects are summarized in Table **[3](#T3){ref-type="table"}**. Cardiac, psychiatric, and neurological adverse effects are the most common reported ones requiring medical care. NPS use may lead to violence, homicidal combative behavior, self-mutilation, coma, and death \[[@R39]\]. Acute toxicity is the leading cause of NPS-induced fatalities. However, concomitant synthetic cathinones and other drugs use have been reported in numerous fatalities, limiting any definitive conclusion regarding their implication in the onset of death.

In 2012, 2.5% of telephone enquiries to the UK National Poisons Information Service and 2.4% of enquiries to US poisons centres are related to recreational drugs \[[@R50]\]. The retrospective telephone call data obtained from the UK Poisons information service showed that 28% of the presumed NPS-intoxicated persons presented agitation \[[@R29]\]. Interestingly, agitation is the most common symptom reported in the retrospective review of self-reported exposures in the Scottish emergency department (prevalence: 26%) \[[@R51]\], in the retrospective study from two US Poison centers (prevalence: 82%) \[[@R52]\], as well as in the prospective US series (prevalence: 66%) \[[@R53]\]. Detailed physical examination at the bedside allows recognizing the sympathomimetic toxidrome including psychosis, significant tachycardia, hypertension, and seizures. Signs attributed to serotonin toxicity are also not rare. Cardiovascular complications are commonly reported including chest pain, palpitation, and collapse. The majority of cathinon-exposed patients is tachycardic with increased systolic and diastolic blood pressure. Cases of cathinone-induced hyponatremia have been reported, questioning the possibility of over hydration in the setting of drug-induced secretion of vasopressin like with MDMA \[[@R54]\]. In a large series of 236 patients exposed to \"bath salts\" and \"legal highs\", bought under 37 separate \"brand\" names in the US and identified as MDPV by gas chromatography/mass spectrometry when performed, the following clinical consequences were described: agitation (82%), combative behavior (57%), tachycardia (56%), hallucinations (40%), paranoia (36%), confusion (35%), chest pain (17%), myoclonus (19%), hypertension (17%), mydriasis (13%), CPK elevations (9%), hypokalemia (4%), and blurred vision (3%) \[[@R52]\].

Management of synthetic cathinone-induced toxicity is primarily supportive and may necessitate admission to the intensive care unit. Intravenous fluids, seizure-prevention measures, close monitoring and restraints are generally recommended to prevent harm to self or others \[[@R37], [@R55], [@R56]\]. Other key-measures include benzodiazepines to treat agitation seizures, and sympathomimetic symptoms; aggressive cooling to treat hyperthermia; water restriction or hypertonic saline to treat hyponatremia; mechanical ventilation to protect airways and treat respiratory failure; fluids and catecholamine infusion to treat shock; and dialysis to treat severe metabolic disturbances and acute renal failure. In the series from the US poison centers, patients were treated and released from the emergency department (49%), admitted to the intensive care unit (21%), admitted to the psychiatry ward (12%) and lost to follow up (12%); additionally, one fatality was reported \[[@R52]\].

### Specific Considerations on the Most Popular Synthetic Cathinones

*Mephedrone*-related psychoactive effects last from 1 to 4 h and resemble those of methamphetamine, including euphoria, elevated mood, alertness, increased concentration, talkativeness, empathy, an "urge to move", pleasurable rushing, sense of being sped up, enhanced music appreciation, elevated mood, and mild sexual stimulation \[[@R40]\]. The higher the dose or the more prolonged the mephedrone use is and, the more severe unwanted effects appear. The first reported death related solely to mephedrone was a Swedish decedent with hyponatremia and brain edema \[[@R61]\]. Several additional cases were attributed to mephedrone, at least as adjunctive causative agent \[[@R62],[@R63]\].

*MDPV*-related psychoactive effects resembling those of cocaine, which lasts from 3 to 4 hours \[[@R41]\]. Its short duration of action leads users to consume numerous doses in succession \[[@R15]\], to counteract the unpleasant comedown effects. MDPV use may result in tolerance and consequently in overdose (42). Recent findings indicated that MDPV has reinforcing properties and activates brain reward circuitry, suggesting a potential for abuse and addiction in humans \[[@R43]\]. Patients using MDPV are prone to development of bizarre behaviors, hallucinations suicidality, and excited delirium syndrome, a condition described with phencyclidine at considerable risk for serious medical morbidity like hyperthermia, rhabdomyolysis, kidney failure and even fatality \[[@R67]-[@R69]\]. MDPV has been detected in up to 107 non-fatal intoxications and 99 deaths, particularly in Finland and in the UK \[[@R34], [@R44]\].

*Methylone,*a close structural analogue of MDMA and the second most popular designer drug used in 2010 and combined to mephedrone \[[@R21]\], is responsible for psychoactive effects resembling those of MDMA \[[@R45]\]. At average doses of 100 to 200 mg, effects of methylone include calmer euphoria, alertness, restlessness, strong feeling of empathy, with milder stimulation. Antidepressant effects, number of significant adverse effects and even fatalities \[[@R74]\] were attributed to methylone use, mainly in association with other illicit drugs.

*4-MEC*, a synthetic stimulant chemically similar to methcathinone with empathogenic effects, is marketed alone and in mixtures containing other synthetic cathinones under the names NRG-1 or NRG-2 \[[@R15]\]. Users report that 4-MEC involves multiple time redosing ("boosting", "bumping"), with difficulty not redosing after using a strong dose if more 4-MEC is available when they are starting to come down. Multidrug poisoning involving 4-MEC as well as acute tolerance to this synthetic cathinone was reported \[[@R46]\].

*Pentedrone*, identified in 2010 as one of the varieties of bath salts throughout the US and UK. Administered by a variety of different routes including intravenously, pentedrone has stimulant effects and a number of adverse effects.

*Naphyrone,*structurally similar to mephedrone and MDPV, is genrally found in mixtures of cathinones, called NRG-1 and NRG-3, mainly including 4-fluoromethcathinone, MDPV, 3\',4\'-methylenedioxy-α-pyrrolidinobutyrophenone (MDPBP), 4\'-methyl-α-pyrrolidinopropiophenone (4-MePPP, MPPP or MαPPP), and β-keto-methylbenzodioxolylpentanamine (pentylone, bk-methyl-K, bk-MBDP). Naphyrone's psychoactive and side-effects are thus rather difficult to distinguish from those of the other NPS present in the mixture. However, one 27-year old male who ingested 1 g of naphyrone was reported to have developed a prolonged high associated with palpitations, sweating and insomnia \[[@R77]\].

CONCLUSION
==========

In the last 8 years, NPS, including synthetic cathinones, has extensively dominated the drug scene in Europe and the US. Many drug users have switched from their traditional drugs to NPS use. Several factors have contributed to their increasing popularity including their falsely legal image, their more reasonable costs, and their distribution based on the new technologies. However, major health issues have emerged in relation to the somatic, mental, and addictive consequences of their use with persistent unknowns for the future. It is mandatory to develop clinical research and improve the management of addiction and poisonings attributed to these NPS.
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###### 

Molecular structure of the most spread synthetic cathinones.

  --
  --

###### 

Classification of the different cathinones according to their relative potential of monoamine reuptake inhibition and release, in comparison to methylenedioxymethamphetamine (MDMA), methamphetamine, and cocaine.

                                        Monamine Reuptake Inhibition   Monoamine Release                    
  ------------------------------------- ------------------------------ ------------------- ---- ----- ----- ----
  **MDMA-like cathinones**                                                                                  
  Mephedrone                            +++                            +++                 ++   ++    ++    ++
  Methylone                             +++                            +++                 ++   ++    ++    ++
  **Methamphetamine-like cathinones**                                                                       
  Cathinone                             ++                             +++                 \+   +++   +++   \-
  Methcathinone                         ++                             +++                 \+   +++   +++   \-
  **Cocaine-like cathinones**                                                                               
  Pyrovalerone                          ++                             +++                 ++   \-    \-    \-
  MDPV                                  ++                             +++                 ++   \-    \-    \-

###### 

Adverse and toxic effects of synthetic cathinones

  Somatic Adverse Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Psychiatric Adverse Effects
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cardiovascular system: tachycardia, hypovolemia, hypertension, chest pain, ST segment alterations, myocarditis, cardiac arrestCentral nervous system: headache, insomnia, dizziness, seizures, tremor, confusion altered mental status, collapse, confusion, dizziness, drowsiness, dystonia, headache, hyperreflexia, myoclonus, paraesthesiasHematologic system: disseminated intravascular coagulation, thrombocytopenia, anemiaGastrointestinal and hepatic system: emesis, nausea, abdominal pain, abnormal liver function tests, liver failurePulmonary system: Shortness of breath, tachypnea, respiratory failure and arrest, respiratory acidosisRenal system: increased serum creatinine, kidney damage, acute renal failure, hyponatremia, hyperkalemia, hyperuricemiaMusculoskeletal system: elevated creatinine kinase, rhabdomyolysis, peripheral vasoconstriction,eOphthalmic system: mydriasis, blurred vision, nystagmusENT: Epistaxis, oral and pharyngeal effects, tongue disorder, trismus, bruxismConsequences of IV route use: vein blockage, skin erosion, local infection, abscess, scab, lump, gangrenous tissue, blood clots and large holes at overused injecting sitesOthers: hyperthermia, skin rash, diaphoresis, bone pain, necrotizing fasciitis, serotonin syndromee   Agitation, aggressionAnxiety, depersonalization/derealization panic attacksAnorexiaParanoia, paranoid delusion, visual and auditory hallucinations (often in the form of threatening people), psychosisAnhedonia, depression, suicidal thoughts/actions, self-harm (gunshots, self-stabbings, repeated self-mutilations) and risk behavior without evidence of psychosis or depression comorbidityCognitive disorders : long-term cognitive impairments, disorientation to names, place and time, loosening of associationAddiction, tolerance, withdrawal
